From the Journals

Office-based screen predicts dementia in Parkinson’s disease


 

FROM JAMA NEUROLOGY

A simple, office-based screening tool was at least as effective as biomarker-based assessments in predicting which patients with Parkinson’s disease are likely to develop dementia in an international study.

©wildpixel/Thinkstock.com
After a mean follow-up of 4.4 years, 11.5% of the study cohort developed dementia. Those who were stratified by the scale as having a low risk of dementia had an annual risk of 0.6%. Those in the intermediate-risk group had a 5.8% annual risk of developing dementia, and those in the high-risk group had a 14.9% annual risk.

Compared with patients in the low-risk group, those in the high-risk group had a 20-fold higher risk of dementia, and those in the intermediate risk group had a 10-fold higher risk (P less than 0.001).

Pages

Recommended Reading

Hepatitis B, C appear to raise Parkinson’s risk
MDedge Internal Medicine
Truncal vagotomy might help delay Parkinson’s disease
MDedge Internal Medicine
Apomorphine pump dramatically decreases ‘off’ time in Parkinson’s
MDedge Internal Medicine
Extended-release amantadine approved for treatment of dyskinesia in Parkinson’s
MDedge Internal Medicine
Exenatide improved motor function in Parkinson’s patients with off-medication symptoms
MDedge Internal Medicine
Poor smell predicts 6-year risk of Parkinson’s
MDedge Internal Medicine
Early cognitive impairment associated with later Parkinson’s disease
MDedge Internal Medicine
Caffeine offers no perks for Parkinson’s patients
MDedge Internal Medicine
Driving ability of Parkinson’s patients can decline quickly
MDedge Internal Medicine
Mutations on LRRK2 gene modify risks for both Crohn’s and Parkinson’s
MDedge Internal Medicine